Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Renalytix AI ( (GB:RENX) ) has shared an announcement.
Renalytix plc announced that all resolutions were passed at its Annual General Meeting. This includes the reappointment of auditors and authorization of share issuance under the equity incentive plan. The successful passage of these resolutions supports the company’s operational strategies and continues its commitment to advance kidney disease management through its FDA-approved test, kidneyintelX.dkd, which is gaining traction in the U.S. healthcare market.
More about Renalytix AI
Renalytix is an artificial intelligence-enabled in vitro diagnostics company that focuses on improving clinical management of kidney disease to enhance patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic tool for early-stage risk assessment of chronic kidney disease, now commercially available in the United States.
YTD Price Performance: -7.33%
Average Trading Volume: 4,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $39.61M
Find detailed analytics on RENX stock on TipRanks’ Stock Analysis page.
